Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Low Frequency Of EGFR Mutations In Pleural Mesothelioma Patients, Cologne, Germany

V. Schildgen, O. Pabst, Ramona-Liza Tillmann, J. Lüsebrink, O. Schildgen, C. Ludwig, Michael Brockmann, E. Stoelben
Published 2015 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
EGFR mutations were previously found in patients suffering from peritoneal mesothelioma but have not yet been described in pleural mesothelioma. The aim of the present study was the identification of EGFR mutations in patients suffering from pleural mesothelioma. Pleural mesothelioma tissue from 31 patients was used to analyze possible mutations in the EGFR gene comprising the exons 18-21 with the codons 719, 768, 790, 858+861, 731+734, 785, 797+801, 831, and 868 with pyrosequencing. The results indicate that 31 pleural mesothelioma patients show a wild-type EGFR gene when analyzing the codons D19, 768, 790, 858+861, 731+734, 785, 797+801, 831, and 868, whereas 2 patients have a mutation in the EGFR gene in codon 719. Sanger sequencing of the EGFR codon 785 was used for the determination of a polymorphism in the sequencing of tumor-free patients and pleural mesothelioma patients with a distribution of a wild-type homozygous sequence with guanine, a wild-type heterozygous sequence having guanine and adenine, a wild-type homozygous sequence with adenine, and a wild-type heterozygous sequence with adenine and guanine. Next, the identification of less EGFR mutations in the EGFR gene of the pleural mesothelioma an up to this time unknown polymorphism in the EGFR gene was identified which could be wrongly interpreted as a mutation.
This paper references
10.1021/bi101843s
Polymorphism of the epidermal growth factor receptor extracellular ligand binding domain: the dimer interface depends on domain stabilization.
Z. Zhang (2011)
Benigne und maligne Mesotheliome: Definition
Jörg Thomas Hartmann (2002)
10.1002/ijc.21271
Common EGFR mutations conferring sensitivity to gefitinib in lung adenocarcinoma are not prevalent in human malignant mesothelioma
J. Cortese (2006)
Epidermal growth factor receptor mutations in malignant pleural and peritoneal mesothelio
Y Enomoto (2012)
Establishment of three novel human malignant pleural mesothelioma cell lines: morphological and cytogenetical studies and EGFR mutation status.
M. Kobayashi (2008)
10.1186/1477-7819-8-88
Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma
J. Foster (2010)
10.1007/978-3-642-10862-4
[Malignant mesothelioma].
J. Espinosa Arranz (1994)
10.1016/j.bcp.2011.07.073
Receptor tyrosine kinase inhibitors and cytotoxic drugs affect pleural mesothelioma cell proliferation: insight into EGFR and ERK1/2 as antitumor targets.
F. Barbieri (2011)
10.1038/nrc2088
Epidermal growth factor receptor mutations in lung cancer
S. Sharma (2007)
10.1097/JTO.0b013e31819c8661
Absence of mutations in the epidermal growth factor receptor (EGFR) kinase domain in patients with mesothelioma.
V. Velcheti (2009)
10.2174/156800910791054130
Gefitinib targets EGFR dimerization and ERK1/2 phosphorylation to inhibit pleural mesothelioma cell proliferation.
R. Favoni (2010)
10.1136/jclinpath-2011-200631
Epidermal growth factor receptor mutations in malignant pleural and peritoneal mesothelioma
Y. Enomoto (2012)
10.1007/s12199-007-0016-7
Current therapies for malignant pleural mesothelioma
T. Nakano (2008)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar